Gilead's breast cancer drug fails to meet main goal of late-stage study

Core Viewpoint - Gilead Sciences announced that its breast cancer drug Trodelvy did not achieve the primary endpoint in a late-stage clinical trial [1] Company Summary - Gilead Sciences is facing a setback with its breast cancer treatment Trodelvy, as the drug failed to meet the main goal in a significant study [1]